Aimei Health Technology (NASDAQ:AFJK) Upgraded at Wall Street Zen

Aimei Health Technology (NASDAQ:AFJK) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of Aimei Health Technology in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Aimei Health Technology Price Performance

NASDAQ:AFJK opened at $55.23 on Friday. The company has a market capitalization of $338.01 million, a P/E ratio of 263.01 and a beta of -3.70. The business has a fifty day simple moving average of $35.47 and a two-hundred day simple moving average of $19.76. Aimei Health Technology has a 1 year low of $6.75 and a 1 year high of $130.37.

Aimei Health Technology (NASDAQ:AFJK) last posted its quarterly earnings results on Tuesday, November 18th. The company reported $0.06 earnings per share for the quarter.

Institutional Trading of Aimei Health Technology

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Crossingbridge Advisors LLC bought a new position in Aimei Health Technology in the second quarter valued at $2,147,000. Berkley W R Corp boosted its holdings in shares of Aimei Health Technology by 23.6% in the 2nd quarter. Berkley W R Corp now owns 425,361 shares of the company’s stock worth $4,704,000 after purchasing an additional 81,235 shares in the last quarter. Clear Street Group Inc. bought a new position in shares of Aimei Health Technology during the 3rd quarter valued at about $691,000. Clear Street LLC raised its holdings in shares of Aimei Health Technology by 63.8% during the 2nd quarter. Clear Street LLC now owns 39,525 shares of the company’s stock valued at $441,000 after buying an additional 15,399 shares in the last quarter. Finally, Wellspring Financial Advisors LLC purchased a new position in shares of Aimei Health Technology during the 2nd quarter valued at about $133,000. Institutional investors own 45.58% of the company’s stock.

About Aimei Health Technology

Aimei Health Technology Co, Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquires businesses in the biopharmaceutical, medical technology/device industries or diagnostic, and other services sectors. Aimei Health Technology Co, Ltd was incorporated in 2023 and is based in New York, New York.